| Filed On | Filing |
|---|---|
| 30 Sep 2026 | 6-K |
| 13 Aug 2026 | 6-K |
| 24 Jun 2026 |
Form 4: Levy Elliott M., Director
Disposed of 23,811,896 Options (Disposition to Issuer) |
| 23 Jun 2026 |
Form 4: Bloss Jeffrey D., Chief Medical Officer
Disposed of 36,539,720 Options (Disposition to Issuer) |
| 08 Jun 2026 | 6-K |
| 01 Jun 2026 | 6-K |
| 14 May 2026 | 6-K |
| 06 May 2026 | 6-K |
| 16 Apr 2026 |
Form 4: Bruce Theresa Margaret Ms, Chief Operating Officer
Granted 132,600,130 Options |
| 01 Apr 2026 |
Form 3: Levy Elliott M., Director
Holds 13 shares of Ordinary Shares |
| 24 Mar 2026 | Form 3: Harrison David James, Head of Translational Medicine |
| 20 Mar 2026 |
Form 3: Mellish Martin C.b., Director
Holds 28 shares of Ordinary Shares |
| 19 Mar 2026 |
Form 3: Bloss Jeffrey D., Chief Medical Officer
Holds 47,136 shares of Ordinary Shares |
| 19 Mar 2026 | S-8 |
| 19 Mar 2026 | 6-K |
| 19 Mar 2026 | 20-F |
| 18 Mar 2026 | SCHEDULE 13D |
| 18 Mar 2026 | Form 3: Webster Ian Alexander, See Remarks |
| 18 Mar 2026 | Form 3: Kay Andrew Martin, Director |
| 18 Mar 2026 | Form 3: Leperlier Cyrille, Director |
Loading...
